Similar Articles |
|
The Motley Fool April 30, 2007 Rich Duprey |
Foolish Forecast: Cutera Zaps Quarter Investors, don't expect the aesthetic laser maker to burn up the growth charts when it reports first-quarter results. |
The Motley Fool May 8, 2007 Rich Duprey |
Cutera's Ugly Quarter The aesthetic laser maker's weak domestic sales dim the outlook for the rest of the year. Investors, take note. |
The Motley Fool February 14, 2006 Rich Duprey |
Cutera's Laser Woes Aesthetic laser maker has a cloudy future of lower sales, earnings, and patent lawsuits. Investors, take note. |
The Motley Fool May 12, 2006 Rich Duprey |
Cutera Continues to Burn The aesthetic laser maker is at risk of losing a patent lawsuit against a competitor. Investors, patents by themselves should not be considered a sufficient competitive moat to induce investment in a company. |
The Motley Fool April 17, 2007 Rich Duprey |
Foolish Forecast: A Bet Candela Can't Afford to Lose The aesthetic laser maker is set to report third-quarter 2007 financial results. Investors, here is what you can expect to see. |
The Motley Fool April 25, 2007 Rich Duprey |
Candela's Amazing Shrinking Quarter The aesthetic laser maker reports its second consecutive quarter of declining sales. Investors, take note. |
The Motley Fool January 10, 2006 Rich Duprey |
Biolase Brightens Outlook The aesthetic laser company expects to be cash flow-neutral on flat revenues. Investors cheer. |
The Motley Fool April 3, 2007 Rich Duprey |
Palomar Medical Burns Another Rival The aesthetic laser maker zaps a privately held firm for patent infringement. But one company not buckling under to Palomar's aggressive tactics is Candela. Investors, take note. |
The Motley Fool September 12, 2006 Rich Duprey |
A Fuzzy Forecast for Candela Based on company-specific trends, the balance of 2006 will be a bust for the aesthetic laser maker. Investors, take note. |
The Motley Fool March 24, 2006 Rich Duprey |
Honing In on Laserscope The medical-use laser manufacturer may get a boost from a laser deal with China. Investors, one deal does not a quarter make, but it could be signal that the tide is turning for this leading medical device laser manufacturer. |
The Motley Fool April 24, 2008 Rich Duprey |
Candela Fizzles Aesthetic laser maker Candela reports slightly higher revenue but wider-than-anticipated losses. |
The Motley Fool April 7, 2008 Rich Duprey |
No Class Act at Candela A class action lawsuit could burn the aesthetic-laser maker. |
The Motley Fool August 22, 2006 Rich Duprey |
Candela Goes Dark Atop recent legal woes, the laser maker reports gloomy quarterly earnings. Investors, take note. |
The Motley Fool May 22, 2006 Rich Duprey |
A Change of Heart for Candela An upgrade of the laser maker points out the futility of watching analysts' shifting opinions. One of the tricks to generating long-term profits is to ignore the shifting winds of analyst sentiment and focus solely on the ability of the company to deliver. |
The Motley Fool May 3, 2006 Rich Duprey |
Candela's Cool Beam The aesthetic laser manufacturer reports steady revenues and profits. Candela's not a cheap stock at these prices, even with the sell-off. |
The Motley Fool November 2, 2005 Rich Duprey |
Can Candela Regain Focus? Aesthetic laser maker reports strong gains, but can it do so consistently? It has new products, new distributors, and new markets to expand into, along with a shareholder-friendly stock buyback program. |
The Motley Fool April 10, 2007 Rich Duprey |
The Beauty of Lasers With aesthetic laser treatments booming, which company looks the best? Candela... Cutera... Palomar Medical Technologies... Cynosure... Syneron... |
The Motley Fool January 17, 2007 Rich Duprey |
Foolish Forecast: Dim Hope for Candela The aesthetic-laser maker will report second-quarter 2007 financial results shortly. Investors, here what to expect. |
The Motley Fool May 5, 2005 Rich Duprey |
Candela Brightens on Sales Growth The laser manufacturer reports record revenues and growing profits. Though not a sell, this stock isn't as hot as expected. |
The Motley Fool November 11, 2008 Brian Orelli |
Two Years of Red Aesthetic laser makers have been rocked over the last few years. |
The Motley Fool September 10, 2007 Rich Duprey |
A Strategic Alternative for Candela In an SEC filing, hedge fund Third Point LLC reports its discussions of "strategic alternatives" at laser maker Candela. Some say a sale was discussed. Investors should take notice. |
The Motley Fool October 26, 2006 Rich Duprey |
Candela's October Surprise The aesthetic laser maker trounces analyst projections, though all may not be what it seems. Investors, take note. |
The Motley Fool March 14, 2008 Rich Duprey |
No Point Man at Candela Activist hedge fund Third Point cuts its stake in the aesthetic laser maker Candela from 9% to only 3.5%. |
The Motley Fool December 14, 2005 Stephen D. Simpson |
An Ugly Battle in Aesthetics Palomar Medical Tech scores an initial win over Cutera in an intellectual property battle, but the war isn't over yet. Investors, take note. |
The Motley Fool January 24, 2007 Rich Duprey |
Candela's Number Is Up The aesthetic laser maker reports dismal results that fall short of its own fuzzy math expectations. |
The Motley Fool February 13, 2007 Rich Duprey |
Palomar's Parallax View A plethora of one-time revenues skewed the aesthetic laser maker's results. Investors, take note. |
The Motley Fool April 22, 2008 Rich Duprey |
Foolish Forecast: No Sizzle at Candela In advance of earnings, analysts expect sales from aesthetic laser maker Candela to be essentially flat. |
The Motley Fool February 17, 2005 Rich Duprey |
Candela Does a Slow Burn Arbitrator rules against laser maker in royalty case. Already reeling from the lackluster sales of lasers that remove varicose veins, tattoos, and the like, Candela's stock plummeted another 10%. |
The Motley Fool January 31, 2008 Rich Duprey |
Candela Investors Burned Again The aesthetic-laser maker continues its string of disappointing quarters. |
The Motley Fool August 18, 2006 Rich Duprey |
Candela Singed by Patent Lawsuit The cosmetic laser maker, hit by rival's claim of infringement, fires back with a counterclaim. Investors, with Candela releasing its earnings report next week, this is sure to be a white hot topic on the conference call. Investors, take note. |
The Motley Fool April 29, 2005 Rich Duprey |
Will Candela Burn Investors Again? Laser maker set to report earnings next week, but spotty record casts doubt on outcome. |
The Motley Fool March 15, 2007 Rich Duprey |
Candela Eases the Pain The aesthetic laser maker acquires an innovative technology that minimizes pain. Investors, it's essentially an investment in the future, but one that still entails some risk. |
The Motley Fool February 13, 2006 Stephen D. Simpson |
Will Syneron Defy History? Publicly traded laser companies have a legacy of failure; will Syneron manage to turn that tide? |
The Motley Fool August 15, 2008 Brian Orelli |
Syneron Medical's Bipolar Growth While U.S. sales sink, international sales are keeping the medical laser making company afloat. |
The Motley Fool May 15, 2006 Stephen D. Simpson |
Sales and Marketing Slam Syneron Higher expenses and disappointing results leave the med-tech stock suffering. |
The Motley Fool February 1, 2006 Rich Duprey |
Candela Is Finally White Hot The aesthetic laser maker finally produces the white-hot sales growth it promised -- two years ago. In midday trading, the stock soared 30%. |
The Motley Fool December 7, 2006 Matt Koppenheffer |
The Best Small Cap for 2007: Syneron This Israel-based aesthetic laser company has financials that need no cosmetic touch-ups. Investors, take note. |
The Motley Fool February 3, 2005 Rich Duprey |
Candela's Lasers Offer Dim View In the cosmetic laser maker's earnings report, it misses its estimates. Revenues, though within the range set by the company, were still at the bottom rung of the ladder at $28.2 million. |
The Motley Fool May 15, 2008 Brian Orelli |
So-So Syneron A little growth is an acceptable outcome in the struggling medical laser industry. |
The Motley Fool August 28, 2007 Rich Duprey |
Candela's Chance to Fan the Flames The maker of lasers used in aesthetic procedures receives FDA approval for an innovative pain reduction technology. Investors, it needs something. Sales have been giving off a pretty weak signal lately, and management admits it has been losing market share. |
The Motley Fool August 26, 2005 Rich Duprey |
Candela Burns Holes in Logic The cosmetic laser manufacturer claims success via questionable mental gymnastics. Perhaps it ought to trim the fat off its verbiage and spare investors any more unneeded workouts. |
The Motley Fool July 30, 2007 Brian Orelli |
Palomar Plummets In the second quarter, cosmetic-laser maker Palomar Medical Technology had a stellar performance in the former, but investors couldn't look past the lack of royalty payments. |
The Motley Fool February 11, 2005 Stephen D. Simpson |
Laser Beamer Lookin' Good Palomar continues to build a profitable business in the highly competitive cosmetic laser market. |
The Motley Fool September 19, 2005 Rich Duprey |
Candela's Beam Not So Hot The laser maker delays filing its annual report as it searches for material weaknesses. Delays in filing its annual reports are head-shaking distractions to performance that investors just don't need. |
The Motley Fool June 14, 2005 Stephen D. Simpson |
Syneron Aims for Cellulite An FDA approval gives Israel's Syneron the lead in non-surgical cellulite treatment. With robust profit margins, that additional revenue could make a big impact on the bottom line. Investors, take note. |
The Motley Fool November 5, 2004 Rich Duprey |
Profit From Management Integrity Laser manufacturer Candela's management avoids taking the easy way out to explain shortfalls. It's a sign of management integrity that will lead to future profits. |
The Motley Fool September 22, 2008 Brian Orelli |
Syneron Irons Out Some Wrinkles The aesthetic device maker gets a new product approved in Europe. |
The Motley Fool September 27, 2007 Brian D. Pacampara |
5 More Turnaround Stocks These companies may be poised for turnarounds: Alberto-Culver, ACI Worldwide, Palomar Medical Technologies, Carter's, and Aspreva Pharmaceuticals. Investors should consider, but with caution. |